ClinicalTrials.gg
CompletedNCT00704288Updated Feb 5, 2024Results posted

Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme

A Phase 2 interventional study of XL184 in Glioblastoma Multiforme, sponsored by Exelixis. Completed at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-05.

Sponsored by Exelixis · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
222
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,302 studies in Glioblastoma with a site in United States — 194 open to participants now, 324 under way, 16 of them phase 3. Glioblastoma · United States.

Enrollment
57th of 1,155
222 · median 33
Started
2008
with 48 others
Phase 2
396 of 1,302
37 open now
Registered
336th of 1,302
by date

Among the 1,302 studies in Glioblastoma with a site in United States, this one is the 57th largest by enrollment of the 1,155 interventional ones that give a count, is one of 49 that started in 2008, is one of 396 in phase 2, and was the 336th registered.

Glioblastoma

2,135 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

194 of the 1,302 studies in Glioblastoma with a site in United States are open now. Recruiting first, the newest first:

189 more — sign in →

All 194 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 338 Glioblastoma studies recruiting now, 233 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,302 studies in Glioblastoma with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the objective response rate and 6-month progression-free survival rate of XL184 in subjects with recurrent or progressive glioblastoma multiforme. XL184 is a new chemical entity that inhibits VEGFR2, MET and RET, kinases implicated in tumor formation, growth and migration.

03

Conditions studied

  • Glioblastoma Multiforme

Keywords

  • GBM
  • Malignant gliomas
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subject has locally determined confirmed diagnosis of Grade 4 astrocytic tumor.
  • The subject has received prior standard radiation for Grade 3 or 4 astrocytic tumor.
  • The subject has received prior temozolomide therapy for Grade 3 or 4 astrocytic tumor (if in first relapse, the subject must have received temozolomide until progression, intolerance, or completion of planned therapy; if in second relapse, the subject must have received temozolomide until progression, intolerance, or completion of planned therapy either for treatment or for treatment after first relapse).
  • The subject is in first or second Grade 4 relapse, defined as having one or two progressions as Grade 4 astrocytic tumor since the original diagnosis of any grade glioma.
  • The subject must have a baseline brain MRI scan within 14 days prior to first dose of XL184 while either not receiving during the 5 days prior to the baseline MRI scan or on a stable dose of glucocorticoids during the 5 days prior to the baseline MRI scan.
  • Subjects having undergone recent resection or of tumor will be eligible as long as all of the following conditions apply: First dose of XL184 occurs at least 28 days after surgery, the subject has recovered from the effects of surgery, and the subject has measurable residual disease.
  • The subject is at least 18 years old.
  • The subject has a (Karnofsky Performance Scale) of ≥ 70%.
  • The subject is capable of understanding the protocol and has signed the document.
  • The subject has adequate organ and marrow function.
  • Sexually active subjects (male and female) must agree to use medically accepted methods of during the course of the study and for 3 months following discontinuation of study drug.
  • Female subjects of must have a negative pregnancy test at enrollment.

Exclusion criteria

Exclusion Criteria:

  • The subject has received non-standard radiation therapy for glioblastoma, non-anti-angiogenic therapy (including agents, small-molecule kinase inhibitors, and biologic agents) or non-cytotoxic hormonal agent within 28 days of the first scheduled dose of XL184 or mitomycin C within 42 days of the first scheduled dose of XL184, other investigational therapy (including agents not specified above) within 28 days of the first scheduled dose of XL184, or prior treatment with nitrosoureas (including carmustine wafer) at any time.
  • Some subjects may not have had any prior VEGF- or VEGFR2-based anti-angiogenic therapy (such as bevacizumab, cediranib, or pazopanib).
  • Some subjects may not have had bevacizumab within 14 days of the first scheduled dose of XL184.
  • The subject is receiving warfarin (or other coumarin derivatives) at study entry and unable to switch to low molecular weight heparin.
  • The subject has evidence of acute intracranial or intratumoral hemorrhage either by MRI or computerized tomography (CT) scan. Subjects with resolving hemorrhage changes, punctate hemorrhage, or hemosiderin may enter the study.
  • The subject is unable to undergo MRI scan (eg, has pacemaker).
  • The subject has received enzyme-inducing anti-epileptic agents within 2 weeks before the first dose of XL184 (eg, carbamazepine, phenytoin, phenobarbital, primidone).
  • The subject has not recovered to National Cancer Institute (CTCAE) v3.0 Grade ≤ 1 from adverse events (AEs) due to surgery, antineoplastic agents, investigational drugs, or other medications that were administered before study enrollment.
  • The subject has evidence of wound dehiscence.
  • The subject is pregnant or breast-feeding.
  • The subject has serious intercurrent illness, such as uncontrolled hypertension, unhealed wounds from recent surgery or cardiac arrhythmias or a recent history of significant disease such as either symptomatic congestive heart failure or unstable angina pectoris within the past 3 months, myocardial infarction within the past 6 months, or active infection requiring systemic treatment/hospitalization within 2 weeks of the first scheduled dose of XL184
  • The subject has inherited bleeding diathesis or coagulopathy with the risk of bleeding.
  • The subject has received any within 28 days or any inactivated vaccine within 7 days prior to first dose of XL184.
  • The subject has had another diagnosis of (unless nonmelanoma skin cancer, in situ carcinoma of the cervix, or a malignancy diagnosed ≥ 2 years previously) or currently has evidence of malignancy (unless non-melanoma skin cancer or in situ carcinoma of the cervix).
  • The subject has a known allergy or to any of the components of the XL184 formulations.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
222 participants (actual)

Study arms

  • Experimental
    Group A cabozantinib 175 mg

    cabozantinib, 175 mg, taken orally once per day (qd).

    Drug: XL184

  • Experimental
    Group B cabozantinib 125 mg

    cabozantinib, 125 mg, taken orally once per day (qd).

    Drug: XL184

  • Experimental
    Group C 125 mg

    cabozantinib, 125 mg, taken orally once per day (qd).

    Drug: XL184

Interventions

  • DrugXL184

    Gelatin capsules supplied in 25-mg and 100-mg strengths; continuous daily dosing

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    Response and progression were determined per modified MacDonald Criteria and modified RANO criteria for GBM using imaging and clinical features

    Time frame: 8 weeks until progressive disease

Secondary outcomes

  1. Duration of Objective Response (Months)

    Duration of response is defined as the time from the first documentation of objective response that was subsequently confirmed at a visit that was ≥ 28 days later to disease progression or death due to any cause.

    Time frame: Assessed during periodically scheduled visits until progressive disease

  2. Progression Free Survival (PFS)

    Response and progression were determined per modified MacDonald Criteria and modified RANO criteria for GBM using imaging and clinical features

    Time frame: Assessed during periodically scheduled visits until progressive disease

  3. Overall Survival (OS)

    Overall survival (OS) is defined as the time from first dose to death due to any cause.

    Time frame: Assessed during periodically scheduled visits until progressive disease

07

Results

Posted Feb 5, 2024

Participant flow

Overall Treatment Period
Participant flow — Overall Treatment Period
MilestoneTreatment Group A (175 mg)Treatment Group B (125 mg)Treatment Group C (125 mg)
Started4659117
Naïve343781
Pre-treated122236
Completed000
Not completed4659117
Withdrew: Adverse event11822
Withdrew: Death001
Withdrew: Physician decision020
Withdrew: Withdrawal by subject013
Withdrew: Disease progression--per modified macdonald criteria (group a)3000
Withdrew: Disease progression--radiologic progression (group b and c)04276
Withdrew: Disease progression--clinical deterioration3611
Withdrew: Roll-over to another study104
Withdrew: Other--subject had intracranial hemorrhage100
Extended Post Treatment Follow Up Period
Participant flow — Extended Post Treatment Follow Up Period
MilestoneTreatment Group A (175 mg)Treatment Group B (125 mg)Treatment Group C (125 mg)
Started4659117
Completed000
Not completed4659117
Withdrew: Death415093
Withdrew: Lost to follow-up021
Withdrew: Withdrawal by subject022
Withdrew: Various reasons5521

Outcome measures

PrimaryObjective Response Rate (ORR)

Response and progression were determined per modified MacDonald Criteria and modified RANO criteria for GBM using imaging and clinical features

Time frame:
8 weeks until progressive disease
Reported as:
Number · percentage of participants
Objective Response Rate (ORR)
percentage of participantsTreatment Group A1 (175 mg) - NaiveTreatment Group B1 (125 mg) - NaiveTreatment Group C1 (125 mg) - NaiveTreatment Group A2 (175 mg) - Pre-TreatedTreatment Group B2 (125 mg) - Pre-TreatedTreatment Group C2 (125 mg) - Pre-Treated
Objective Response Rate (ORR)17.627.08.88.305.6
SecondaryDuration of Objective Response (Months)

Duration of response is defined as the time from the first documentation of objective response that was subsequently confirmed at a visit that was ≥ 28 days later to disease progression or death due to any cause.

Time frame:
Assessed during periodically scheduled visits until progressive disease
Reported as:
Median · Months
Duration of Objective Response (Months)
MonthsTreatment Group A1 (175 mg) - NaiveTreatment Group B1 (125 mg) - NaiveTreatment Group C1 (125 mg) - NaiveTreatment Group A2 (175 mg) - Pre-TreatedTreatment Group B2 (125 mg) - Pre-TreatedTreatment Group C2 (125 mg) - Pre-Treated
Duration of Objective Response (Months)5.913 (2.760 to 12.812)8.541 (3.778 to 9.264)NA (2.792 to NA)NA (NA to NA)—4.172 (NA to NA)
SecondaryProgression Free Survival (PFS)

Response and progression were determined per modified MacDonald Criteria and modified RANO criteria for GBM using imaging and clinical features

Time frame:
Assessed during periodically scheduled visits until progressive disease
Reported as:
Median · Months
Progression Free Survival (PFS)
MonthsTreatment Group A1 (175 mg) - NaiveTreatment Group B1 (125 mg) - NaiveTreatment Group C1 (125 mg) - NaiveTreatment Group A2 (175 mg) - Pre-TreatedTreatment Group B2 (125 mg) - Pre-TreatedTreatment Group C2 (125 mg) - Pre-Treated
Progression Free Survival (PFS)3.712 (1.905 to 5.092)4.698 (3.647 to 9.231)3.712 (2.562 to 3.712)3.285 (0.953 to NA)1.807 (1.675 to 3.745)2.300 (2.201 to 2.464)
SecondaryOverall Survival (OS)

Overall survival (OS) is defined as the time from first dose to death due to any cause.

Time frame:
Assessed during periodically scheduled visits until progressive disease
Reported as:
Median · Months
Overall Survival (OS)
MonthsTreatment Group A (175 mg) - NaiveTreatment Group A (175 mg) - Pre-TreatedTreatment Group B (125 mg) - NaiveTreatment Group B (125 mg) - Pre-TreatedTreatment Group C (125 mg) - NaiveTreatment Group C (125 mg) - Pre-Treated
Overall Survival (OS)7.671 (5.913 to 13.502)4.074 (1.380 to 16.689)10.381 (7.260 to 16.393)4.221 (1.971 to 5.716)10.217 (8.016 to 12.122)4.583 (2.792 to 5.683)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment Group A (175 mg)41/46 (89.1%)24/46 (52.2%)46/46 (100%)
Treatment Group B + Group C (125 mg)144/176 (81.8%)90/176 (51.1%)176/176 (100%)
Most frequent serious events
Showing 10 of 108
Most frequent serious events
EventTreatment Group A (175 mg)Treatment Group B + Group C (125 mg)
ConvulsionNervous system disorders6/4613/176
Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders2/4612/176
DiarrhoeaGastrointestinal disorders3/462/176
Confusional StatePsychiatric disorders3/464/176
Deep Vein ThrombosisVascular disorders0/4610/176
HemiparesisNervous system disorders0/468/176
NauseaGastrointestinal disorders2/463/176
Wound DehiscenceInjury, poisoning and procedural complications2/463/176
Troponin I IncreasedInvestigations2/460/176
DehydrationMetabolism and nutrition disorders1/466/176
Most frequent other events
Showing 10 of 118
Most frequent other events
EventTreatment Group A (175 mg)Treatment Group B + Group C (125 mg)
FatigueGeneral disorders35/46132/176
DiarrhoeaGastrointestinal disorders31/4697/176
Decreased AppetiteMetabolism and nutrition disorders22/4666/176
ConstipationGastrointestinal disorders22/4654/176
HeadacheNervous system disorders20/4659/176
HypertensionVascular disorders18/4656/176
DysphoniaRespiratory, thoracic and mediastinal disorders18/4649/176
NauseaGastrointestinal disorders17/4665/176
Palmar-Plantar Erythrodysaesthesia SyndromeSkin and subcutaneous tissue disorders17/4656/176
StomatitisGastrointestinal disorders17/4631/176

Baseline characteristics

Age, Customized
Age, Customized(Participants)Treatment Group A (175 mg)Treatment Group B + Group C (125 mg)Total
18 to <45113344
45 to <55115364
55 to <65186179
65 to <7562834
>= 75011
Sex: Female, Male
Sex: Female, Male(Participants)Treatment Group A (175 mg)Treatment Group B + Group C (125 mg)Total
Female156883
Male31108139
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment Group A (175 mg)Treatment Group B + Group C (125 mg)Total
American Indian or Alaska Native022
Asian145
Native Hawaiian or Other Pacific Islander000
Black or African American358
White40158198
More than one race000
Unknown or Not Reported279
08

Study locations

8 sites
  • University of California, Los Angeles
    Los Angeles, California 90095, United States
  • University of California, San Francisco
    San Francisco, California 94143, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02115, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • Duke University, The Preston Robert Tisch Brain Tumor Center
    Durham, North Carolina 27710, United States
  • University of Texas M.D. Anderson Cancer Center
    Houston, Texas 77030, United States
  • University of Virginia Health System
    Charlottesville, Virginia 22908, United States
  • University of Washington
    Seattle, Washington 98195, United States
09

References and documents

Publications

  • Ellingson BM, Aftab DT, Schwab GM, Hessel C, Harris RJ, Woodworth DC, Leu K, Chakhoyan A, Raymond C, Drappatz J, de Groot J, Prados MD, Reardon DA, Schiff D, Chamberlain M, Mikkelsen T, Desjardins A, Holland J, Ping J, Weitzman R, Wen PY, Cloughesy TF. Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma. Neuro Oncol. 2018 Sep 3;20(10):1411-1418. doi: 10.1093/neuonc/noy054. PubMed 29660005 ↗
  • Cloughesy TF, Drappatz J, de Groot J, Prados MD, Reardon DA, Schiff D, Chamberlain M, Mikkelsen T, Desjardins A, Ping J, Holland J, Weitzman R, Wen PY. Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy. Neuro Oncol. 2018 Jan 22;20(2):259-267. doi: 10.1093/neuonc/nox151. PubMed 29036345 ↗
  • Wen PY, Drappatz J, de Groot J, Prados MD, Reardon DA, Schiff D, Chamberlain M, Mikkelsen T, Desjardins A, Holland J, Ping J, Weitzman R, Cloughesy TF. Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy. Neuro Oncol. 2018 Jan 22;20(2):249-258. doi: 10.1093/neuonc/nox154. PubMed 29016998 ↗
  • Ellingson BM, Harris RJ, Woodworth DC, Leu K, Zaw O, Mason WP, Sahebjam S, Abrey LE, Aftab DT, Schwab GM, Hessel C, Lai A, Nghiemphu PL, Pope WB, Wen PY, Cloughesy TF. Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials. Neuro Oncol. 2017 Jan;19(1):89-98. doi: 10.1093/neuonc/now187. Epub 2016 Aug 31. PubMed 27580889 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2008, a primary completion of Jun 2012 and a completion of Dec 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2024, 11 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2008
First posted
Jun 24, 2008
Start
May 2008
Primary completionActual
Jun 2012
CompletionActual
Dec 2012
Results first posted
Feb 5, 2024
Last update
Feb 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00704288
Lead sponsor
Exelixis
Responsible party
Sponsor
First posted
Jun 24, 2008
Start date
May 2008
Primary completion
Jun 2012
Completion
Dec 2012
Results posted
Feb 5, 2024
Last update
Feb 5, 2024
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cabozantinib

Start the discussion